Currently, Immuno-oncology market has witnessed a high number of advancements. The competition between the players is intensifying.
- Advertising -
The biotechnology and pharmaceutical companies are striving to achieve first mover advantage by launching new and most effective therapies. This therapy is expected to be a game-changing approach to treating cancer.
- Advertising -
Browse the report: www.orbisresearch.com/reports/index/immuno-oncology-market-by-type-mab-naked-conjugate-cancer-vaccines-immune-checkpoint-inhibitors-pd-1-pd-l1-ctla-4-by-application-lung-melanoma-leukemia-lymphoma-global-forecast-to-2022
The report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022” provides a detailed analysis of the current and future market scenario of the global Immuno-oncology market with a brief overview of the industry. The report also provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth.
In addition, the report also highlights various opportunities available for growth of the global Immuno-oncology market.
According to this edition of the report, the Immuno-oncology market is anticipated to hit billions of dollars within the next 5-10 years. The report also provides the sales of major marketed Immuno-oncology drugs.
On the basis of type of product, the global Immuno-oncology market has been segmented into major product classes including monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme prodrug therapy and radio immunotherapy).
Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America was estimated to account for the largest share.
Request a sample of the report: www.orbisresearch.com/contacts/request-sample/333558
Primarily, the Immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.
Moreover, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, we have provided information about the Immuno-oncology programs at various stages of clinical development.
The study also provides a comprehensive overview of various aspects of the clinical trials in the Immuno-oncology market, such as phases, and product type. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.
The latter part of the report discusses some of the prominent players in the Immuno-oncology market. Some of the key players dominant in the market are Amgen, Bristol-Myers Squibb, F.
Hoffmann-La Roche, and Merck among others. A brief business overview of each player has been provided, along with their product and pipeline portfolios and recent developments.
Access the email@example.com/contact/purchase/333558
Overall, Immuno-oncology is an important and rapidly emerging field, which deserves the attention it has been receiving in recent years; and thus the report will prove as a complete source of knowledge and analysis for clients and potential investors.
List of Tables:
Table 6-1: Ongoing Trials for Avastin
Table 6-2: Ongoing Trials for Herceptin
Table 6-3: Ongoing Trials for ADCETRIS
Table 6-4: Ongoing Trials for Kadcyla
Table 6-5: Ongoing Trials for Blincyto
Table 6-6: Ongoing Trials for Other Monoclonal Antibodies
Table 6-7: Ongoing Trials for Provenge
Table 6-8: Ongoing Trials for Pediarix/ Infanrix
Table 6-9: Ongoing Trials for Yervoy
Table 6-10: Ongoing Trials for Opdivo
Table 6-11: Ongoing Trials for Keytruda
Table 6-12: Ongoing Trials for Other Immuno-Oncology Products
List of Figures:
Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2016
Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2022
Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-4: Global - Avastin Market (Billion US$), 2012-2015
Figure 6-5: Global - Herceptin Market (Billion US$), 2012-2015
Figure 6-6: Global - ADCETRIS Market (Million US$), 2012-2015
Figure 6-7: Global - Kadcyla Market (Billion US$), 2013-2016
Figure 6-8: Global - Blincyto Market (Million US$), 2014-2016
Figure 6-9: Global - Other Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-10: Global - Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022
Category: Market Research Publishers and RetailersCompany profile: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from the leading publishers and authors across the gl obe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their need, and we produce the perfect requi ...
For more information: